Wilmington, NC, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Off The Hook YS Inc. (NYSE: “OTH”, or “Off the Hook Yachts” ), America’s largest buyer and seller of pre-owned boats, is reminding U.S. boat buyers that the “One Big Beautiful Bill Act” (OBBBA), signed into law in July 2025, has reinstated 100% bonus depreciation for qualifying business assets—including boats and yachts—through January 19, 2026. This powerful tax incentive allows eligible buyers to deduct the entire purchase price of a qualifying vessel in t ...

Core Insights - MKS Inc. will participate in a fireside chat at the Nasdaq 53 Investor Conference on December 9, 2025, at 6:00 a.m. EST [1] - A live webcast of the session will be available on the company's Investor Relations website, with a replay accessible for a limited time afterward [2] Company Overview - MKS Inc. is a global provider of enabling technologies that transform various industries, focusing on semiconductor manufacturing, electronics, packaging, and specialty industrial applications [3] - The company delivers foundational technology solutions, including instruments, subsystems, systems, process control solutions, and specialty chemicals technology, aimed at improving process performance and optimizing productivity [3] - MKS's solutions address challenges related to miniaturization and complexity in advanced device manufacturing, enhancing power, speed, features, and connectivity [3]

New Netskope One platform capabilities deliver visibility and access control for MCP, the emerging standard that enables AI agents to connect to enterprise data and toolsSANTA CLARA, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Netskope (NASDAQ: NTSK), a leader in modern security and networking for the cloud and AI era, today announced breakthrough security capabilities for Model Context Protocol (MCP) communications. These enhancements are part of the Netskope One platform, which helps organizations confident ...

FREEHOLD, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced a series of Q3 2025 advancements for KetoAir™, including expanded deployment, the launch of a first-responder metabolic health program, and entry into an international market. Key Highlights Launched Holistic Health Reset Program with First Responders in NevadaIn August 2025, Avalon, together with Saga Health and Specialty ...

JERUSALEM, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present in the following investor conferences in December 2025. Event:37th Annual Piper Sandler Healthcare ConferenceFormat:Fireside ChatDate:December 3, 2025Time:1:00 – 1:25PM ETLocation:New York, NY Event:<td style="max-width:80%; width:80%; min-width:80%;;border-top: ...

LONDON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Arqit Quantum Inc. (“Arqit”), a leader in quantum safe encryption, announced it will report financial results for the fiscal year ending September 30, 2025 on Tuesday, December 9, 2025. In conjunction with this announcement, Arqit will host a conference call at 11:00 a.m. ET / 8:00 a.m. PT on December 9, 2025 with the Company’s CEO, Andy Leaver, and CFO, Nick Pointon. A live webcast of the call will be available on the “News & Events” page of the Company’s website ...

EFFINGHAM, Ill., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (Nasdaq: MSBI) today announced that its wholly owned subsidiary, Midland States Bank (“the Company”), has sold substantially all of its equipment finance portfolio to an affiliate of North Mill Equipment Finance LLC (“NMEF”). The transaction closed on November 28, 2025. NMEF acquired the portfolio for $502 million in cash, subject to adjustment. As of October 31, 2025, the equipment finance portfolio consisted of approximately $ ...

Core Insights - NeOnc Technologies Holdings, Inc. announced preclinical findings indicating that ultrasound enhances the therapeutic potency of NEO100, showing strong antitumor effects across various brain tumor types [1][3] Group 1: Research and Development - The study conducted at the University of Southern California (USC) utilized an AI-driven, 3D-bioprinted New Approach Methodology (NAM) to identify NEO100 as a leading sonodynamic therapy agent [2] - The NAM platform, based on NTHI-patented rapid magnetic 3D bioprinting technology, allows for the quick generation of patient-derived tumor organoids, significantly accelerating biomedical research [2] - An AI-driven neural network was employed to predict compounds likely to respond to focused ultrasound, with NEO100 consistently identified as a leading sonosensitizer [3] Group 2: Clinical Implications - Validation studies on bioprinted tumor spheroids demonstrated that NEO100, when combined with focused ultrasound, exhibited enhanced tumor-killing activity across various brain tumors, supporting its advancement into future clinical trials [3] - The integration of AI, 3D bioprinting, and ultrasound expands NEO100's commercial and clinical opportunities beyond current indications, as stated by the Executive Chairman of NTHI [4] Group 3: Company Overview - NeOnc Technologies Holdings, Inc. focuses on developing therapeutics for central nervous system cancers, with a drug development platform that includes NEO100 and NEO212, both in Phase II clinical trials [5] - The company has a patent portfolio extending to 2038, covering various drug candidates and delivery methods aimed at overcoming the blood-brain barrier [5]

CHATSWORTH, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- XYRA Corp., a subsidiary of Cavitation Technologies, Inc. (OTCQB: CVAT), an AI-driven, quantum-secure payment network uniting remittances, fintech, and crypto assets under one tokenized, compliant infrastructure, today announced that it has secured a license agreement that will enable XYRA to accept and process digital assets in real time, such as USDC stablecoin, as well as leading cryptocurrencies like Bitcoin, Ethereum, and Tether, with instant conver ...

Core Insights - Cadrenal Therapeutics, Inc. has appointed Dr. Lee Scott Golden as an independent director to its Board of Directors, effective immediately [1][3] - Dr. Golden brings over 25 years of experience in the biopharmaceutical industry, particularly in cardiovascular medicine and anticoagulation therapy [2][3] - The company aims to develop novel anticoagulants to address significant unmet needs in both acute and chronic anticoagulation therapy [4] Company Overview - Cadrenal Therapeutics focuses on developing innovative biopharmaceutical products that improve anticoagulation therapy by providing greater predictability, stability, and fewer bleeding complications [4] - The company currently has two clinical-stage assets: tecarfarin, an oral vitamin K antagonist for chronic use, and frunexian, a parenteral small-molecule Factor XIa antagonist for acute hospital settings [4] - The mission is to reshape standards of care in anticoagulation by targeting underserved patient populations [4]